CCR6 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population from the HAP1 near-haploid cell line, carrying heterogeneous CCR6 mutations that abolish receptor function. The polyclonal format avoids clonal biases, offering a representative model for CCR6 studies. Supplied as live cells, they are ready for functional assays and drug discovery.
HAP1 is a near-haploid human leukemia cell line originally derived from a patient with chronic myeloid leukemia, serving as an established platform for genetic screening and hematopoietic malignancy modeling. Its near-haploid karyotype, with only one copy of most chromosomes, enables unambiguous gene targeting and clean phenotypic interpretation, making it ideal for CRISPR-based knockout studies. The HAP1 background provides a controlled system to investigate CCR6-mediated signaling and migration in a hematopoietic context.
CCR6 encodes a G-protein-coupled receptor that specifically binds the chemokine CCL20, mediating chemotaxis of Th17 cells and dendritic cells to inflamed mucosal sites. Ligand engagement activates G??i/o proteins, triggering calcium flux and downstream signaling through PI3K-AKT, MAPK (ERK1/2), and JAK-STAT3 cascades. The receptor is regulated by pro-inflammatory cytokines such as TNF-alpha, IL-1??, and TGF-beta, and its activity is modulated by interactions with ??-arrestin and GRK kinases. Downstream effectors include STAT3, NF-??B, AKT, ??-catenin, and MMP9, linking CCR6 signaling to gene programs controlling adhesion, invasion, and cytokine production.
Disruption of CCR6 in HAP1 cells abolishes CCL20-induced chemotaxis, enabling dissection of the receptor??s role in immune cell trafficking and metastasis. The near-haploid background minimizes genetic redundancy, facilitating direct assessment of proliferation and migration. This knockout model recapitulates impaired dendritic cell and Th17 recruitment, underscoring CCR6??s significance in mucosal immunity and its therapeutic relevance in autoimmunity, inflammatory bowel disease, and HIV infection.
These polyclonal knockout cells are suitable for chemotaxis and migration/invasion assays, flow cytometry, calcium flux measurements, and Western blot analysis of phospho-AKT, -ERK1/2, and -STAT3. They can be employed in xenograft metastasis models and for validating inhibitors targeting the CCL20-CCR6 axis. The product accelerates functional genomics and drug target validation in a hematopoietic context. For further technical details, please contact Ascent Research.
